A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Phase 2 Recruiting 22 enrolled M.D. Anderson Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.

Timeline

Start: 2025-09-25
Primary completion: 2029-12-31
Completion: 2031-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Calaspargase Pegol	Protein / enzyme biologic	—	Intravenous
Subject	Decitabine	Small molecule	—	Intravenous
Subject	Venetoclax	Small molecule	—	Oral

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Summary

Timeline

Drugs

Indications